Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I randomized, double-blind, placebo-controlled, single ascending dose study of RGLS4326 in healthy volunteers

Trial Profile

Phase I randomized, double-blind, placebo-controlled, single ascending dose study of RGLS4326 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs RGLS 4326 (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 04 Jan 2019 According to a Regulus Therapeutics media release, the company is planning to discuss data from the cohort 1 of MAD study, results from the completed this SAD study and the interim data (13 weeks ) of 27 week preclinical study with the FDA , to resume the further dosing of the MAD study.
    • 04 Jan 2019 Status changed from recruiting to completed, according to a Regulus Therapeutics media release.
    • 07 Mar 2018 According to a Regulus Therapeutics media release, company planning for the multiple ascending dose (MAD) portion is underway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top